Literature DB >> 21918114

National prevalence estimates for cytomegalovirus IgM and IgG avidity and association between high IgM antibody titer and low IgG avidity.

Sheila C Dollard1, Stephanie A S Staras, Minal M Amin, D Scott Schmid, Michael J Cannon.   

Abstract

Primary cytomegalovirus (CMV) infection of the mother during pregnancy presents risk of CMV infection of the fetus with resulting permanent disability. CMV IgM antibody is generated following primary CMV infection but also can appear during nonprimary CMV infection and is thus of limited diagnostic use by itself. In contrast, the presence of low CMV IgG avidity has been shown to be a unique and reliable serologic indicator of primary CMV infection. We measured CMV IgG and IgM antibody levels and IgG avidity in sera from a population sample of 6,067 U.S. women aged 12 to 49 years from NHANES (National Health and Nutrition Examination Survey). The CMV IgG prevalence was 58% overall and increased strongly with age. The CMV IgM prevalence was 3.0% overall and remained relatively flat across age groups. The prevalence of low IgG avidity was 2.0% overall, decreased sharply with age, and was seen mainly among IgM-positive sera. Fourteen to 18% of the CMV IgM-positive sera were low IgG avidity, presumably representing primary CMV infection. High CMV IgM antibody titer was a strong predictor of low IgG avidity. The ability to reliably identify primary CMV infection during pregnancy is important for management of the pregnancy, including possible treatment options for the fetus. Both IgM and IgG avidity measurements provide useful clinical information for evaluating primary CMV infection, although commercial tests for CMV IgG avidity are not yet widely available in the United States.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21918114      PMCID: PMC3209034          DOI: 10.1128/CVI.05228-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  25 in total

1.  Ability of three IgG-avidity assays to exclude recent cytomegalovirus infection.

Authors:  M Bodéus; D Beulné; P Goubau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-04       Impact factor: 3.267

2.  Validation of an in-house assay for cytomegalovirus immunoglobulin G (CMV IgG) avidity and relationship of avidity to CMV IgM levels.

Authors:  Harry E Prince; Amy L Leber
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

3.  Maternal IgG avidity and IgM detected by blot as diagnostic tools to identify pregnant women at risk of transmitting cytomegalovirus.

Authors:  T Lazzarotto; S Varani; P Spezzacatena; L Gabrielli; P Pradelli; B Guerra; M P Landini
Journal:  Viral Immunol       Date:  2000       Impact factor: 2.257

4.  Antibody response to cytomegalovirus after renal transplantation: comparison of patients with primary and recurrent infections.

Authors:  R F Pass; P D Griffiths; A M August
Journal:  J Infect Dis       Date:  1983-01       Impact factor: 5.226

5.  Comparative evaluation of eight commercial human cytomegalovirus IgG avidity assays.

Authors:  Maria Grazia Revello; Emilia Genini; Giovanna Gorini; Catherine Klersy; Antonio Piralla; Giuseppe Gerna
Journal:  J Clin Virol       Date:  2010-06-18       Impact factor: 3.168

6.  Differentiation of primary cytomegalovirus infection from reactivation using the urea denaturation test for measuring antibody avidity.

Authors:  N K Blackburn; T G Besselaar; B D Schoub; K F O'Connell
Journal:  J Med Virol       Date:  1991-01       Impact factor: 2.327

7.  Evaluation of an in-house specific immunoglobulin G (IgG) avidity ELISA for distinguishing recent primary from long-term human cytomegalovirus (HCMV) infection.

Authors:  Silmara de Souza; Sandra H A Bonon; Sandra C B Costa; Cláudio L Rossi
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2004-01-26       Impact factor: 1.846

8.  Recent rubella virus infection indicated by a low avidity of specific IgG.

Authors:  K Hedman; I Seppälä
Journal:  J Clin Immunol       Date:  1988-05       Impact factor: 8.317

9.  Congenital cytomegalovirus infection: The relative importance of primary and recurrent maternal infection.

Authors:  S Stagno; R F Pass; M E Dworsky; R E Henderson; E G Moore; P D Walton; C A Alford
Journal:  N Engl J Med       Date:  1982-04-22       Impact factor: 91.245

10.  Kinetics of specific immunoglobulins M, E, A, and G in congenital, primary, and secondary cytomegalovirus infection studied by antibody-capture enzyme-linked immunosorbent assay.

Authors:  S L Nielsen; I Sørensen; H K Andersen
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

View more
  31 in total

1.  GWAS, cytomegalovirus infection, and schizophrenia.

Authors:  Jakob Grove; Anders D Børglum; Brad D Pearce
Journal:  Curr Behav Neurosci Rep       Date:  2014-12-01

2.  Seroprevalence of cytomegalovirus among children 1 to 5 years of age in the United States from the National Health and Nutrition Examination Survey of 2011 to 2012.

Authors:  Tatiana M Lanzieri; Deanna Kruszon-Moran; Minal M Amin; Stephanie R Bialek; Michael J Cannon; Margaret D Carroll; Sheila C Dollard
Journal:  Clin Vaccine Immunol       Date:  2014-12-17

3.  Influence of parity and sexual history on cytomegalovirus seroprevalence among women aged 20-49 years in the USA.

Authors:  Tatiana M Lanzieri; Deanna Kruszon-Moran; Manoj Gambhir; Stephanie R Bialek
Journal:  Int J Gynaecol Obstet       Date:  2016-06-29       Impact factor: 3.561

4.  Potential impact of different cytomegalovirus (CMV) IgM assays on an algorithm requiring IgM reactivity as a criterion for measuring CMV IgG avidity.

Authors:  Harry E Prince; Mary Lapé-Nixon; Andrew Brenner; Nancy Pitstick; Marc Roger Couturier
Journal:  Clin Vaccine Immunol       Date:  2014-03-26

5.  Performance of a cytomegalovirus IgG enzyme immunoassay kit modified to measure avidity.

Authors:  Harry E Prince; Mary Lapé-Nixon; Susan M Novak-Weekley
Journal:  Clin Vaccine Immunol       Date:  2014-03-26

6.  Association of Cytomegalovirus and Toxoplasma gondii Antibody Titers With Bipolar Disorder.

Authors:  Mark A Frye; Brandon J Coombes; Susan L McElroy; Lori Jones-Brando; David J Bond; Marin Veldic; Francisco Romo-Nava; William V Bobo; Balwinder Singh; Colin Colby; Michelle K Skime; Joanna M Biernacka; Robert Yolken
Journal:  JAMA Psychiatry       Date:  2019-12-01       Impact factor: 21.596

7.  Telomere length in blood and skeletal muscle in relation to measures of glycaemia and insulinaemia.

Authors:  S Ahmad; A Heraclides; Q Sun; T Elgzyri; T Rönn; C Ling; B Isomaa; K-F Eriksson; L Groop; P W Franks; O Hansson
Journal:  Diabet Med       Date:  2012-10       Impact factor: 4.359

8.  Production of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.

Authors:  Kirsten Schneider-Ohrum; Corinne Cayatte; Yi Liu; Zhaoti Wang; Alivelu Irrinki; Floro Cataniag; Nga Nguyen; Stacie Lambert; Hui Liu; Shahin Aslam; Greg Duke; Michael P McCarthy; Louise McCormick
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

9.  Lack of human cytomegalovirus expression in single cells from glioblastoma tumors and cell lines.

Authors:  Travis S Johnson; Zachary B Abrams; Xiaokui Mo; Yan Zhang; Kun Huang
Journal:  J Neurovirol       Date:  2017-07-10       Impact factor: 2.643

10.  Cytomegalovirus IgG Level and Avidity in Breastfeeding Infants of HIV-Infected Mothers in Malawi.

Authors:  Athena P Kourtis; Jeffrey Wiener; Tiffany S Chang; Sheila C Dollard; Minal M Amin; Sascha Ellington; Dumbani Kayira; Charles van der Horst; Denise J Jamieson
Journal:  Clin Vaccine Immunol       Date:  2015-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.